<DOC>
	<DOCNO>NCT00764309</DOCNO>
	<brief_summary>The purpose study evaluate safety Dasatininb treatment scleroderma pulmonary interstitial fibrosis .</brief_summary>
	<brief_title>Safety Evaluation Dasatinib Subjects With Scleroderma Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Target Population meet American College Rheumatology ( ACR ) criteria scleroderma clinical evidence active skin disease skin score ≥15 onset first nonRaynaud phenomenon feature SSc 3 year prior screen evidence fibrosing alveolitis ( active pulmonary fibrosis ) manifest forced vital capacity ( FVC ) 45 % 80 % predict normal and/or diffusing capacity ( DLCO ) 30 % 70 % predict normal value abnormal high resolution Computed tomography ( CT ) scan chest/lungs demonstrate typical ground glass change alveolitis background fibrosis adequate renal function evidence renal crisis 2 month prior enrollment serum creatinine &lt; 3 mg/dL sex , must use acceptable form birth control age ≥ 18 Clinically significant pleural pericardial effusion previous 12 month : Grade 3 4 . Patients recent Grade I II effusion peripheral edema permit enter study Clinically significant cardiac disease ( New York Heart Association Class III IV ) include preexist arrhythmia , ( ventricular tachycardia , ventricular fibrillation , `` Torsade de Pointes '' ) , myocardial infarction , uncontrolled angina within 6 month , congestive heart failure , cardiomyopathy , pericardial disease Clinicallysignificant coagulation platelet function disorder ( eg , know von Willebrand 's disease ) Abnormal QTcF interval prolong ( &gt; 450 msec ) electrolytes correct baseline electrocardiogram Laboratory Test Findings Hgb &lt; 10 g/dL ; platelet count &lt; 100,000/dL ; WBC &lt; 3,000/dL ; PMN &lt; 1,000/dL ; OR lymphocytes &lt; 350/dL The presence follow laboratory finding screen : positive antibody hepatitis C virus ; positive antibody hepatitis B surface antigen ( HBsAg ) ; serum bilirubin 2 time normal , Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) &gt; 2.5 time upper limit normal Prohibited Treatments and/or Therapies use immunosuppressive therapy must discontinue enrollment , eg methotrexate , azathioprine , cyclophosphamide , mycophenolic acid , mycophenolate mofetil , cyclosporine treatment experimental investigational drug ( ) concurrently less 12 week prior study enrollment use antifibrotic agent must discontinue enrollment , eg colchicine , D‑penicillamine , minocycline Type 1 oral collagen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>